CHIN-HSIAO TSENG2020-06-012020-06-0120141753-0393https://www.scopus.com/inward/record.uri?eid=2-s2.0-84906251728&doi=10.1111%2f1753-0407.12149&partnerID=40&md5=773138137786083dc2744c5aac18de70https://scholars.lib.ntu.edu.tw/handle/123456789/496091[SDGs]SDG3acarbose; acetylsalicylic acid; angiotensin receptor antagonist; calcium channel blocking agent; clopidogrel; dipeptidyl carboxypeptidase inhibitor; dipyridamole; fibric acid derivative; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin; metformin; nonsteroid antiinflammatory agent; pioglitazone; rosiglitazone; sulfonylurea; ticlopidine; 2,4 thiazolidinedione derivative; antidiabetic agent; pioglitazone; adult; aged; article; cancer risk; comorbidity; dose response; female; human; insulin treatment; major clinical study; male; non insulin dependent diabetes mellitus; priority journal; Taiwan; thyroid cancer; treatment duration; Diabetes Mellitus, Type 2; insulin resistance; middle aged; protection; risk assessment; risk factor; Thyroid Neoplasms; time; treatment outcome; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Protective Factors; Risk Assessment; Risk Factors; Taiwan; Thiazolidinediones; Thyroid Neoplasms; Time Factors; Treatment Outcomejournal article10.1111/1753-0407.12149246464212-s2.0-84906251728